🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Thank you to the Cancer Discovery Board of Scientific Editors for a productive meeting yesterday at #AACR23! We are so grateful for your support!

Second a recreation of an iconic photograph taken 35 years apart! Drew Pardoll Luis Diaz

Pale Blue Dot is a photo of Earth that was taken by the Voyager 1 space probe in 1990 from a distance of about 6 billion kilometers (3.7 billion miles) as it was leaving our solar system. This is what Carl Sagan said about the photo: "Look again at that dot. That's here. That's

Delighted to see this in print-only possible with wonderful collaborators and mentors Mike Foote @BenjcRousseau Zsofia Stadler Luis Diaz Fergus Keane MSK Department of Medicine nature.com/articles/s4159…

So excited to share our data on #LynchSyndrome and risk of new neoplasia after immunotherapy Thank you to our terrific colleagues Emily Harrold Mike Foote @BenjcRousseau Luis Diaz and many others MSK Department of Medicine

Fascinating You can pretty much survive anything in feety pajamas

BLAKE. CORUM.

Durable complete responses to PD-1 blockade alone in mismatch repair deficient locally advanced rectal cancer #ASCO24 👉100% cCR, no relapse & no additional therapy 👉20 pts with sustained response of 12mo 👉ctDNA as an early marker of response 🧐Just amazing efficacy… ESMO - Eur. Oncology

An analysis of published studies suggests that a longer duration of immune checkpoint inhibitor therapy is associated with a higher incidence of complete response among patients with mismatch repair–deficient cancers. Full correspondence: nej.md/3EXiEpe

12 lessons students learn in the Sinclair Lab: Lesson 1. Write the way you speak

Breakthrough immunotherapy drug dostarlimab spares cancer patients from harsh surgeries, with tumors vanishing in many cases! 🩺 #CancerResearch #Immunotherapy The New York Times Memorial Sloan Kettering Cancer Center GSK nytimes.com/2025/04/27/hea…

New paper from our team at Memorial Sloan Kettering Cancer Center. Nonoperative Management of Mismatch Repair–Deficient Tumors | New England Journal of Medicine nejm.org/doi/10.1056/NE…

An experimental immunotherapy treatment at Memorial Sloan Kettering Cancer Center is offering new hope for patients with certain early-stage cancers. CBS News’ Jonathan LaPook, M.D explains how it works.

Immunotherapy has revolutionised the treatment of mismatch repair-deficient colorectal cancer Here's the story in 5 papers🧵 1. The seminal work (NEJM, 2015) showed that immunotherapy is much more effective in mismatch repair-deficient (vs. -proficient) colorectal cancer:

This is an amazing paper that finds, in certain cancers (early-stage, mismatch repair-deficient) immunotherapy can replace surgery This meant that 3 of the patients with rectal cancer went on to have healthy children, which wouldn't have been possible with current care

We’re almost halfway through 2025 and we’re already seeing incredible tech. Here’s the 20 most incredible tech reveals of 2025 so far. A thread. 1. Joby Aviation releases their first ever electric taxi helicopter.

6. T-cell fighting cancer cell

A genuine pleasure + honour to meet up again with rock🌟 Prof Le and her fellow Eric before KEYNOTE 16 presentation #ASCO25. It’s where it all began for IO in dMMR GI cancer. Am ever grateful for coming on board KEYNOTE 177 Luis Diaz and discuss how far we have gone since! 🧐🙌

Our preview of two very interesting papers. One from Dr Bardelli's lab, the other from Dr Diaz's group. Bardelli Lab Luis Diaz Cancer Cell